Piper Jaffray Reiterates Neutral as Endo Int'l (ENDP) Announces Paul Campanelli as New CEO

Piper Jaffray reiterated a Neutral rating and $19.00 price target on Endo International plc (NASDAQ: ENDP) following the company's announcement appointment of Paul Campanelli as CEO effective immediately. Mr. Campanelli was responsible for the 2014 acquisition of JHP Pharma, which gave Par a sizable generic injectibles business and more importantly gave the company Vasostrict and other 505(b) (2)-based injectable products in development.

Analyst David Amsellem commented, "Endo announced that the Board of Directors has named Paul Campanelli as President and CEO effective immediately. Given that the majority of revenue and EBITDA comes from the generics business, it was only logical that someone as seasoned in the generics space as Mr. Campanelli (recall that he was the CEO of Par for 3 years up until its acquisition by ENDP) would eventually lead the company. That said, we do not believe that ENDP is well positioned for sustainable value creation given the state of its balance sheet and its relative inability to de-lever significantly, and as such, we continue to believe that an aggressive approach to the divestiture of non-core assets (even if it means jettisoning Xiaflex) is warranted. We reiterate our Neutral rating and $19 PT."

For an analyst ratings summary and ratings history on Endo International plc click here. For more ratings news on Endo International plc click here.

Shares of Endo International plc closed at $23.39 yesterday.

You May Also Be Interested In

• TrueBlue's (TBI) PeopleScout Announces Appointments to its Executive Team
• Dave & Buster's Entertainment (PLAY) Appoints Darin Harper as CFO
• IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down